About the Presenter:

Laura Rippy
Chris Sklarin | Managing Partner
Chris has over 20 years’ experience in tech investing, product development, and sales engineering. He has invested over $60M in companies from seed to venture stage. Most recently, he was Vice President at Edison Partners, where he focused on investments for Enterprise 2.0 and mobile. Previously, Chris was a Director of Business Development with biomedical venture accelerator BioEnterprise and Director of Business Development with Chrysalis Ventures. Earlier, at JumpStart, a nationally recognized venture development organization, he sourced and executed seed investments. Chris has an SB EE from MIT (’88) and an MBA from the University of California at Berkeley’s Haas School of Business.

 

Castor Ventures Interviews Kinsa Founder and CEO

Currently, Kinsa’s smart, cloud-connected thermometers and data analytics may be THE solution to help us track the virus and thus be much more equipped to respond. As the New York Times reported in mid-March, Kinsa’s data was the first to point out the spread of COVID-19 by recognizing a spike in the abnormal temperatures being measured by users. The impact of their data also was recently featured in this longer article: Restrictions Are Slowing Coronavirus Infections, New Data Suggest.

During this discussion, we’ll discuss Inder’s background and Kinsa’s origin story before diving into the latest maps, data sets, and insights he is watching as we move into the next phase of dealing with COVID-19: reopening our economy.

Founded in 2012, Kinsa is a health technology company based in San Francisco with a mission of helping stop the spread of infectious disease. Alumni Ventures Group’s Castor Fund 1 invested in Kinsa in 2016, alongside Kleiner Perkins.

 
 

Connect with Us